Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Domchek

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Contemporary Clinical Trials|January 7, 2015
Women In Steady Exercise Research (WISER) Sister: study design and methodsKathryn H Schmitz, Nancy I Williams, Despina Kontos, et al.
Breast Cancer Research and Treatment|October 30, 2015
Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trialKathryn H Schmitz, Nancy I Williams, Despina Kontos, et al.
European Journal of Medical Genetics|November 15, 2025
An electronic review of clinical outcomes after return of actionable genetic research results from a health system research biobankGiorgio Cocchella, Lillian Phung, Elisabeth Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
Elife|February 3, 2026
Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentYouyou Zhang, Mu Xu, Jiao Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2005
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck, Tara Friebel, Theresa Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO GuidelineNadine Tung, Charité Ricker, Hans Messersmith, et al.
BMC Medical Ethics|April 1, 2026
A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study)Anuja Rajendra Godbole, Elisabeth Wood, Brian Egleston, et al.
BMC Cancer|October 24, 2025
The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testingDaniel Chavez-Yenter, Dominique Fetzer, Brian Egleston, et al.
Scientific Reports|June 25, 2013
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick, Richard Morgan, Francesca Launchbury, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Contemporary Clinical Trials|January 7, 2015
Women In Steady Exercise Research (WISER) Sister: study design and methodsKathryn H Schmitz, Nancy I Williams, Despina Kontos, et al.
Breast Cancer Research and Treatment|October 30, 2015
Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trialKathryn H Schmitz, Nancy I Williams, Despina Kontos, et al.
European Journal of Medical Genetics|November 15, 2025
An electronic review of clinical outcomes after return of actionable genetic research results from a health system research biobankGiorgio Cocchella, Lillian Phung, Elisabeth Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
Elife|February 3, 2026
Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentYouyou Zhang, Mu Xu, Jiao Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2005
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck, Tara Friebel, Theresa Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO GuidelineNadine Tung, Charité Ricker, Hans Messersmith, et al.
BMC Medical Ethics|April 1, 2026
A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study)Anuja Rajendra Godbole, Elisabeth Wood, Brian Egleston, et al.
BMC Cancer|October 24, 2025
The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testingDaniel Chavez-Yenter, Dominique Fetzer, Brian Egleston, et al.
Scientific Reports|June 25, 2013
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick, Richard Morgan, Francesca Launchbury, et al.
Pageof 10